Skip to main content
SpringerLink
Log in

The Cost of Alzheimer’s Disease

Will Drug Treatment Ease the Burden?

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Evans D. Estimated prevalence of Alzheimer’s disease in the United States. Milbank Q 1990; 68: 267–89

    Article  PubMed  CAS  Google Scholar 

  2. Cotton P. Constellation of risks and processes seen in search for Alzheimer’s clues. JAMA 1994; 271: 89–91

    Article  PubMed  CAS  Google Scholar 

  3. Small GW. Tacrine for treating Alzheimer’s disease [editorial]. JAMA 1992; 268: 2564–5

    Article  PubMed  CAS  Google Scholar 

  4. Odenheimer GL. Management of patients with Alzheimer’s disease. Pharmacotherapy 1991; 11: 237–41

    PubMed  CAS  Google Scholar 

  5. Max W. The economic impact of Alzheimer’s disease. Neurology 1993; 43 Suppl. 4: S6–1O

    Google Scholar 

  6. Hu T, Huang L, Cartwright W. Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist 1986; 26: 158–63

    Article  PubMed  CAS  Google Scholar 

  7. Huang L, Cartwright W, Hu T. The economic cost of senile dementia in the United States, 1985. Public Health Rep 1988; 103: 3–7

    PubMed  CAS  Google Scholar 

  8. Ernst RL, Hay JW. The US economic and social costs of Alzheimer’s disease revisited. Am J Public Health 1994; 84: 1261–4

    Article  PubMed  CAS  Google Scholar 

  9. Gray A, Renn P. Alzheimer’s disease: the burden of the illness in England. Health Trends 1993; 25 (1): 31–7

    PubMed  CAS  Google Scholar 

  10. Rice DR, Fox PJ, Max W, et al. The economic burden of Alzheimer’s disease care. Health Aff 1993; 12: 165–76

    Google Scholar 

  11. Max W, Webber PA, Fox PJ. Alzheimer’s disease: the unpaid burden of caring. J Aging Health 1995; 7 (2): 179–99

    Article  PubMed  CAS  Google Scholar 

  12. Welch HG, Walsh JS, Larson EB. The cost of institutional care in Alzheimer’s disease: nursing home and hospital use in a prospective cohort. J Am Geriatr Soc 1992; 40: 221–4

    PubMed  CAS  Google Scholar 

  13. Weinberger M, Gold DT, Divine GW, et al. Expenditures in caring for patients with dementia who live at home. Am J Public Health 1993; 83: 338–41

    Article  PubMed  CAS  Google Scholar 

  14. Stommel M, Collins CE, Given BA. The costs of family contributions to the care of persons with dementia. Gerontologist 1994; 34 (2): 199–205

    Article  PubMed  CAS  Google Scholar 

  15. Summers WK, Majovski LV, Marsh GM, et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315 (20): 1241–5

    Article  PubMed  CAS  Google Scholar 

  16. Eagger SA, Levy R, Sabakian BJ. Tacrine in Alzheimer’s disease. Lancet 1991; 337: 989–92

    Article  PubMed  CAS  Google Scholar 

  17. Davis KL, Thai LJ, Gamzu ER, et al. A double-blind, placebocontrolled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med 1992; 327 (18): 1253–9

    Article  PubMed  CAS  Google Scholar 

  18. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992; 268: 2523–9

    Article  PubMed  CAS  Google Scholar 

  19. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271: 985–91

    Article  PubMed  CAS  Google Scholar 

  20. Davies B, Andrewes D, Stargatt R, et al. Tacrine in Alzheimer’s disease [letter]. Lancet 1989; 2: 163–4

    Article  PubMed  CAS  Google Scholar 

  21. Chatellier G, Lacomblez L. Tacrine (tetrabydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. BMJ 1990; 300: 495–9

    Article  PubMed  CAS  Google Scholar 

  22. Gauthier S, Bouchard R, Lemontagne A, et al. Tetrabydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer’s disease: results of a Canadian double-blind, crossover, multicenter study. N Engl J Med 1990; 322 (18): 1272–6

    Article  PubMed  CAS  Google Scholar 

  23. Molloy DW, Guyatt GH, Wilson DB, et al. Effect oftetrabydroaminoacridine on cognition, function and behaviour in Alzheimer’s disease. Can Med Assoc J 1991; 144 (1): 29–34

    CAS  Google Scholar 

  24. Maltby N, Broe GA, Creasey H, et al. Efficacy of tacrine and lecithin in mild to moderate Alzheimer’s disease: doubleblind trial. BMJ 1994; 308: 879–83

    Article  PubMed  CAS  Google Scholar 

  25. Winker MA. Tacrine for Alzheimer’s disease: which patient, what dose? [editorial]. JAMA 1994; 271: 1023–4

    Article  PubMed  CAS  Google Scholar 

  26. Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer’s disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982; 139 (11): 1421–4

    PubMed  CAS  Google Scholar 

  27. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer’s disease. Am J Psychiatry 1985; 142 (1): 28–33

    PubMed  CAS  Google Scholar 

  28. Mundell I. Is tacrine worth the price? Inpharma 1993; 910: 3–4

    Google Scholar 

  29. Wolf-Klein GP. New Alzheimer’s drug expands your options in symptom management. Geriatrics 1993; 48 (8): 26–36

    PubMed  CAS  Google Scholar 

  30. Lubeck DP, Mazonson PD, Bowe T. Potential effect of tacrine on expenditures for Alzheimer’s disease. Med Interface 1994; 7 (10): 130–8

    PubMed  CAS  Google Scholar 

  31. Dejong R, Osterlund OW, Roy GW. Measurement of quality-of- life changes in patients with Alzheimer’s disease. Clin Ther 1989; 11 (4): 545–54

    PubMed  CAS  Google Scholar 

  32. Coast J. Developing the QALY concept: exploring the problems of data acquisition. PharmacoEconomics 1993; 4: 240–6

    Article  PubMed  CAS  Google Scholar 

  33. Beto JA, Bansal VK. Quality of life in treatment of hypertension: a metaanalysis of clinical trials. Am J Hypertens 1992; 5: 125–3

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Health & Aging, University of California, N-631Y, San Francisco, California, 94143-0612, USA

    Wendy Max

Authors
  1. Wendy Max
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Max, W. The Cost of Alzheimer’s Disease. Pharmacoeconomics 9, 5–10 (1996). https://doi.org/10.2165/00019053-199609010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199609010-00002

Keywords

Search

Navigation